Diffusion Weighted Imaging in Predicting Progression Free Survival in Patients with Squamous Cell Carcinomas of the Head and Neck Treated with Induction Chemotherapy

被引:38
作者
Berrak, Su [1 ,4 ]
Chawla, Sanjeev [1 ]
Kim, Sungheon [1 ,5 ]
Quon, Harry [2 ]
Sherman, Eric [3 ,6 ]
Loevner, Laurie A. [1 ]
Poptani, Harish [1 ]
机构
[1] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Hematol Oncol, Philadelphia, PA 19104 USA
[4] Monmouth Med Ctr, Childrens Hosp, Dept Pediat, Long Branch, NJ USA
[5] NYU, Dept Radiol, New York, NY 10016 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
Head and neck cancer; squamous cell carcinoma; diffusion weighted MRI; apparent diffusion coefficient; induction chemotherapy; survival; MAGNETIC-RESONANCE-SPECTROSCOPY; TREATMENT RESPONSE; COMPUTED-TOMOGRAPHY; MOUSE MODEL; IN-VIVO; NEOADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; TUMOR RESPONSE; 9.4; T; CANCER;
D O I
10.1016/j.acra.2011.06.009
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
100231 [临床病理学]; 100902 [航空航天医学];
摘要
Rationale and Objectives: The aim of this study was to assess the role of diffusion-weighted imaging in predicting progression-free survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with induction chemotherapy. Materials and Methods: Eighteen patients with HNSCC underwent diffusion-weighted imaging studies prior to treatment and within 3 weeks after completion of induction chemotherapy. Median apparent diffusion coefficient (ADC) values were computed from the largest cervical metastatic lymph node. Percentage changes in ADC values from pretreatment to posttreatment time points were compared between alive and dead patients using the Mann-Whitney U test. P values < .05 were considered statistically significant. Results: A 22% increase in ADC was observed after induction chemotherapy in alive patients (n = 15), while patients who died from HNSCC (n = 3) demonstrated a 33% decrease in ADC. The difference in percentage change in ADC between alive and dead patients was significant (P = .039). Conclusions: ADC may be a useful marker in predicting progression-free survival in patients with HNSCC undergoing induction chemotherapy.
引用
收藏
页码:1225 / 1232
页数:8
相关论文
共 48 条
[1]
Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: Clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy [J].
Bentzen, SM ;
Ruifrok, ACC ;
Thames, HD .
RADIOTHERAPY AND ONCOLOGY, 1996, 38 (02) :89-101
[2]
Bezabeh T, 2005, AM J NEURORADIOL, V26, P2108
[3]
DOSE, VOLUME, AND TUMOR-CONTROL PREDICTIONS IN RADIOTHERAPY [J].
BRENNER, DJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (01) :171-179
[4]
Chenevert TL, 1997, CLIN CANCER RES, V3, P1457
[5]
ADVANCED SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX: EFFICACY OF POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY FOR DETERMINING PRIMARY TUMOR RESPONSE DURING INDUCTION CHEMOTHERAPY [J].
Chepeha, Douglas B. ;
Sacco, Assuntina G. ;
Oxford, Lance E. ;
Karamchandani, Rahul ;
Miller, Tamara H. ;
Teknos, Theodoros N. ;
Bradford, Carol R. ;
Eisbruch, Avraham ;
Worden, Frank M. ;
Urba, Susan G. ;
Mukherji, Suresh K. ;
Bui, Chuong ;
Frey, Kirk A. ;
Wolf, Gregory T. ;
Lee, Julia S. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2009, 31 (04) :452-460
[6]
CHU E, 2005, CANC PRINCIPLES PRAC, P296
[7]
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma [J].
Denis, F ;
Garaud, P ;
Bardet, E ;
Alfonsi, M ;
Sire, C ;
Germain, T ;
Bergerot, P ;
Rhein, B ;
Tortochaux, J ;
Calais, G .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :69-76
[8]
Tumor volume: a basic and specific response predictor in radiotherapy [J].
Dubben, HH ;
Thames, HD ;
Beck-Bornholdt, HP .
RADIOTHERAPY AND ONCOLOGY, 1998, 47 (02) :167-174
[9]
ENSLEY JF, 1984, CANCER-AM CANCER SOC, V54, P811, DOI 10.1002/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO
[10]
2-E